Relatively recent IPO AVROBIO (AVRO +8.6%) has been a star performer since its debut on June 21. Shares are up over 150% from its $19 offer price and up 65% from its opening print of $29.50.
The gene therapy developer’s pipeline includes candidates for Fabry disease, Gaucher, Pompe and cystinosis.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.